Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bluebird Bio
(NQ:
BLUE
)
0.4908
+0.0043 (+0.88%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bluebird Bio
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
21
22
Next >
Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2023
July 19, 2023
Via
Benzinga
AT&T, Carvana, Northern Trust, And Other Big Stocks Moving Higher On Wednesday
July 19, 2023
U.S. stocks traded higher, with the Dow Jones gaining over 250 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
The Latest Analyst Ratings for bluebird bio
June 01, 2023
Via
Benzinga
Why Is Bluebird Bio (BLUE) Stock Up 17% Today?
April 28, 2023
Bluebird Bio received a major lift from JPMorgan Chase regarding its gene-editing therapeutic, sending BLUE stock flying.
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
July 19, 2023
Via
Benzinga
Why bluebird bio Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
July 19, 2023
Gainers 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) shares surged 23.6% to $2.99 in pre-market trading after dipping 21% on Tuesday.
Via
Benzinga
Cisco To Rally Around 21%? Here Are 10 Other Analyst Forecasts For Wednesday
July 19, 2023
Wedbush boosted the price target for Domino's Pizza, Inc. (NYSE: DPZ) from $365 to $430. Wedbush analyst Nick Setyan maintained an Outperform rating. Domino's shares rose 0.7% to close at $392.29 on...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
July 19, 2023
It's time for another dive into the biggest pre-market stock movers as we check out all of the latest news for Wednesday!
Via
InvestorPlace
Down 51% in 2023, Here's Why Bluebird Bio Stock Could Soon Double, Says Wall Street
June 30, 2023
This company could soon commercialize its third gene therapy.
Via
The Motley Fool
This 1 Problem Could Sink at Least 4 Gene-Editing Stocks
June 29, 2023
Reaching profitability could be harder than investors expect.
Via
The Motley Fool
Is Bluebird Bio Stock a Buy Now?
June 29, 2023
If the company can pull off a comeback, investors who get in now will see incredible returns. But how likely is a comeback?
Via
The Motley Fool
bluebird bio Announces FDA Priority Review of the Biologics License Application for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
June 21, 2023
From
bluebird bio, Inc.
Via
Business Wire
2 Short-Squeeze Candidates That Could Go Parabolic
June 15, 2023
Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately.
Via
The Motley Fool
Breakthrough in CRISPR-Based Therapy: FDA Accepts Vertex and CRISPR Therapeutics' Exa-cel Application
June 09, 2023
The FDA has accepted the application for Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG (NASDAQ: CRSP) exa-cel for sickle cell disease and transfusion-dependent
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2023
June 01, 2023
Via
Benzinga
Caterpillar To Rally Over 37%? Here Are 10 Other Analyst Forecasts For Thursday
June 01, 2023
Keybanc boosted the price target for Pure Storage, Inc. (NYSE: PSTG) from $35 to $40. Keybanc analyst Thomas Blakey maintained the stock with an Overweight rating. Pure Storage shares fell 2.1% to...
Via
Benzinga
Genprex (NASDAQ: GNPX) Releases New Patient Video Interview Describing Positive Experience in Clinical Trial
June 01, 2023
A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ: GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that...
Via
Benzinga
Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You?
May 21, 2023
It's facing a few issues that are practically guaranteed to affect shareholder returns.
Via
The Motley Fool
bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress
May 09, 2023
From
bluebird bio, Inc.
Via
Business Wire
Why RH Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 16, 2023
Gainers GD Culture Group Limited (NASDAQ: GDC) shares climbed 121.9% to $9.63 after gaining over 8% on Monday. GD Culture recently announced an $11.55 million registered direct offering.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
May 04, 2023
Via
Benzinga
1 Incredibly Undervalued Growth Stock to Buy Hand Over Fist in May
May 04, 2023
This market-beating biotech stock still has more room to run.
Via
The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
April 28, 2023
Via
Benzinga
Why First Republic Bank Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
April 28, 2023
Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 268% to $3.42 after dropping around 8% on Thursday.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2023
April 28, 2023
Via
Benzinga
Intel, Saia, Charter Communications And Other Big Stocks Moving Higher On Friday
April 28, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events
April 27, 2023
From
bluebird bio
Via
Business Wire
Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday
April 25, 2023
U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
With FDA Submission For Sickle Cell Gene Therapy, Bluebird Bio Can Potentially Have 3 Approved Products By 2023
April 24, 2023
Via
Benzinga
bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
April 24, 2023
From
bluebird bio, Inc.
Via
Business Wire
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
21
22
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.